Emicizumab: 12 agencies, 2018–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) has been harder on emicizumab than on its own caseload: it refused 2 of 6 decisive submissions here (33%), against a base rate of 11% across everything it has assessed.
Assessment has run over 8.2 years, from 29 Mar 2018 at AWMSG (Wales) to 26 May 2026 at AWMSG (Wales).
AOTMIT (Poland) changed its position: not recommended on 8 Dec 2023, restricted by 12 Aug 2025, after a resubmission.
No assessment is on file from PBAC (Australia) and SMC (Scotland), each among the eight highest-volume agencies here.
The file is active: 16 of 35 records date from 2023 or later.
AWMSG (Wales) was first to assess emicizumab, on 29 Mar 2018; CIPM (Spain) did not open a file until 20 Mar 2024 — a wide spread of 6 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 8 years in total.
12 of the 12 agencies here assessed emicizumab more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
emicizumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for emicizumab reads 17 recommended, 9 not recommended, 4 restricted and 2 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 29 Dec 2025 | Tratamento profilático de pacientes com hemofilia A grave ou com nível de atividade de fator VIII inferior a 2%, sem ant… | incorporated into SUS | source |
| AOTMIT (Poland) | 12 Aug 2025 | programu lekowego „Zapobieganie krwawieniom u pacjentów z hemofilią A niepowikłaną inhibitorem czynnika VIII (ICD-10: D6… | recommended conditionally | source |
| CIPM (Spain) | 19 Jun 2024 | Indicación terapéutica autorizada: Hemlibra está indicado para la profilaxis de rutina de los episodios de sangrado en p… | not financed by the SNS · art. 92 c, d, e | source |
| NYE METODER (Norway) | 26 May 2024 | Rutineprofylakse ved alvorlig hemofili A uten antistoff mot faktor VIII der behandling med FVIII er vurdert som uegnet e… | introduced with conditions | source |
| HAS (France) | 27 Mar 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
30 further decisions for emicizumab, across 12 agencies, are not shown here. They include the most recent record on file, 26 May 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- marstacimab — divergent outcome (recommended vs restricted) on a shared indication
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- concizumab — same ATC class B02B — Antihemorrhagics
- etranacogene dezaparvovec — same ATC class B02B — Antihemorrhagics
Coverage: 35 decisions for emicizumab from 12 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.